JP2003525206A - 低用量ＩＬ−１βによる網膜異形成を伴わない光受容細胞の救済を誘発する方法 - Google Patents

低用量ＩＬ−１βによる網膜異形成を伴わない光受容細胞の救済を誘発する方法

Info

Publication number
JP2003525206A
JP2003525206A JP2000616241A JP2000616241A JP2003525206A JP 2003525206 A JP2003525206 A JP 2003525206A JP 2000616241 A JP2000616241 A JP 2000616241A JP 2000616241 A JP2000616241 A JP 2000616241A JP 2003525206 A JP2003525206 A JP 2003525206A
Authority
JP
Japan
Prior art keywords
dystrophic
composition
retinal
site
retina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000616241A
Other languages
English (en)
Japanese (ja)
Inventor
クラッセン，ヘンリー
ホワイトレイ，シモン，ジェイ．
ヤング，マイケル，ジェイ．
Original Assignee
ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド filed Critical ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド
Publication of JP2003525206A publication Critical patent/JP2003525206A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2000616241A 1999-05-06 2000-05-08 低用量ＩＬ−１βによる網膜異形成を伴わない光受容細胞の救済を誘発する方法 Pending JP2003525206A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13285599P 1999-05-06 1999-05-06
US60/132,855 1999-05-06
PCT/US2000/012565 WO2000068267A1 (fr) 1999-05-06 2000-05-08 RECUPERATION DE CELLULES PHOTORECEPTRICES INDUITE PAR IL-1β ADMINISTREE A FAIBLE DOSE ET NE PROVOQUANT PAS DE DYSPLASIE RETINIENNE

Publications (1)

Publication Number Publication Date
JP2003525206A true JP2003525206A (ja) 2003-08-26

Family

ID=22455907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000616241A Pending JP2003525206A (ja) 1999-05-06 2000-05-08 低用量ＩＬ−１βによる網膜異形成を伴わない光受容細胞の救済を誘発する方法

Country Status (5)

Country Link
EP (1) EP1179020A4 (fr)
JP (1) JP2003525206A (fr)
AU (1) AU4994000A (fr)
CA (1) CA2372738A1 (fr)
WO (1) WO2000068267A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667968A (en) * 1989-08-30 1997-09-16 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
AU677951B2 (en) * 1992-02-14 1997-05-15 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors

Also Published As

Publication number Publication date
AU4994000A (en) 2000-11-21
CA2372738A1 (fr) 2000-11-16
WO2000068267A9 (fr) 2001-06-14
EP1179020A1 (fr) 2002-02-13
WO2000068267A1 (fr) 2000-11-16
EP1179020A4 (fr) 2004-08-18

Similar Documents

Publication Publication Date Title
DE60021760T2 (de) Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
DE69729796T2 (de) Verwendung von synergistischen zusammensetzungen von il-12 und ifn-alpha für die behandlung von infektiösen krankheiten
EP2139467B1 (fr) Neuroprotection dans des maladies démyélinisantes
Old Tumor necrosis factor
EP1871382B1 (fr) Methodes destinees au traitement d'une lesion au niveau du systeme nerveux central, dans lesquelles est utilise un protocole d'administration a reduction progressive
Bauer et al. Macrophage-depletion influences the course of murine HSV-1 keratitis
Kadiu et al. Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases
DE69635708T2 (de) Tetrandrin zur behandlung von augenentzündungen
Ksander et al. Cell-mediated immune tolerance to HSV-1 antigens associated with reduced susceptibility to HSV-1 corneal lesions.
Barak et al. Involvement of brain cytokines in the neurobehavioral disturbances induced by HIV-1 glycoprotein120
US5624938A (en) Use of chloroquine to treat multiple sclerosis
Berthe et al. Toxicologic and pharmacokinetic analysis of intravitreal injections of foscarnet, either alone or in combination with ganciclovir.
DE69928932T2 (de) Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung
Whiteley et al. Photoreceptor rescue after low-dose intravitreal IL-1β Injection in the RCS Rat
JP2003525206A (ja) 低用量ＩＬ−１βによる網膜異形成を伴わない光受容細胞の救済を誘発する方法
JPH01233226A (ja) 抗ウイルス薬剤の製造への乳蛋白の利用
Gorantla et al. Modulation of innate immunity by copolymer‐1 leads to neuroprotection in murine HIV‐1 encephalitis
Aloe et al. Nerve growth factor: basic findings and clinical trials
KR20150059671A (ko) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 파킨슨 증후군의 예방 또는 치료용 약제학적 조성물
US8106096B2 (en) Compositions and methods for treatment of optic nerve diseases
WO2022242768A1 (fr) Utilisation d'un composé pyrrolopyrimidine
WO1994012667A1 (fr) Inhibiteurs de metabolites d'acide arachidonique destine a la prevention de deteriorations neurologiques
WO2022170845A1 (fr) Utilisation d'un nanomatériau d'or pour inhiber le coronavirus
CA1332222C (fr) Composition pharmaceutique pour la prevention et le traitement des maladies causees par une deficience immunitaire primaire
CN116650482A (zh) 3-typ在制备治疗自身免疫性脱髓鞘疾病药物中的应用